Novo Nordisk begins selling new insulin pen in U.K.

Novo Nordisk ($NVO), one of the world's largest insulin providers, said that the company has brought its new disposable, prefilled insulin pen called FlexTouch to market in the U.K., providing diabetics there with a new method of delivering its fast-acting insulin analogue, NovoRapid. The disposable pen, which has a push-button system, appears to be designed to make it easy for patients to get very specific doses of insulin. One of the big problems in diabetes treatment is poor blood sugar control among patients, and major players in the industry such as Novo Nordisk, Eli Lilly ($LLY) and Sanofi ($SNY) have developed insulin pens and expanded the options patients have to get insulin doses to combat their disease. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.